Hydrogel Encapsulation of Genome-Engineered Stem Cells for Long-Term Self-Regulating Anti-Cytokine Therapy

Area of Science:

• Biotechnology
• Stem Cell Therapy
• Rheumatology

Background:

• Biologic therapies for rheumatoid arthritis (RA) require continuous high-dose administration, risking adverse events.
• A need exists for responsive drug delivery systems to manage RA flares effectively.

Purpose of the Study:

• To create an injectable, responsive drug delivery system for RA treatment.
• To engineer induced pluripotent stem cells (iPSCs) to produce interleukin-1 receptor antagonist (IL-1Ra) in response to disease markers.

Main Methods:

• Generated genome-edited iPSCs expressing IL-1Ra under the control of the Ccl2 promoter.
• Encapsulated engineered iPSCs in injectable agarose hydrogels fabricated using 3D printed molds.
• Evaluated therapeutic efficacy and implant longevity in the K/BxN mouse model of inflammatory arthritis.

Main Results:

• Subcutaneous injection of Ccl2-IL1Ra iPSC-laden hydrogels significantly reduced inflammatory arthritis severity in mice.
• The injectable hydrogel system demonstrated improved implant longevity compared to previous scaffold methods.
• The delivery system showed potential for minimally invasive, long-term cell-based therapy.

Conclusions:

• A minimally invasive, injectable cell-based drug delivery system using engineered iPSCs shows therapeutic promise for inflammatory arthritis.
• This adaptable strategy may be applicable to other autoimmune and chronic diseases.
• The approach simplifies implantation and enhances therapeutic potential for RA treatment.